Livmoniplimab

Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors[1][2].

[1] Tindall RR, et al. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024 Mar 4;14:1362247. DOI:10.3389/fonc.2024.1362247
[2] Guo J, et al. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies. Int Immunopharmacol. 2024 Mar 30;130:111782. DOI:10.1016/j.intimp.2024.111782